Therapy Selection News Today

/PRNewswire/ -- Companion Diagnostics Market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029,...

Operator: Good afternoon. Thank you for attending the Guardant Health Q4 2024 Earnings Call. My name is Victoria and Ill be your moderator today.

Guardant Health, Inc. (NASDAQ:GH) Q4 2023 Earnings Call Transcript February 22, 2024 Guardant Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. Thank you for attending the Guardant Health Q4 2024 Earnings Call. My name is Victoria […]

Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million ...

Guardant Health, Inc. , a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $155.1 million for the fourth quarter of...

Lisa Schrade, PharmD, and Robert Sidonio Jr, MD, MSc, explore the integral partnership between specialty pharmacists and hematologists in managing patients with hemophilia.

Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million ...

Robert Sidonio Jr, MD, MSc, discusses patient-centered therapy choices, highlighting the diverse options and considerations for hemophilia A treatment.

/PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to...

The Business Research Company’s Liquid Biopsy Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032